Navigation Links
Brookhaven Lab and BioSET Inc. patent improved growth factor technology
Date:7/13/2010

UPTON, NY Brookhaven Science Associates, the company that manages the U.S. Department of Energy's Brookhaven National Laboratory, and Biosurface Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have been issued a U.S. patent for an improved second-generation technology for designing synthetic peptides that are important for tissue regeneration. These bioactive peptides are designed to communicate growth signals to cells of damaged tissue in order to foster efficient, rapid healing.

BioSET has an exclusive license for producing these peptides, which hold promise for improving the body's healing response in numerous applications of tissue repair. Developed at Brookhaven Lab, these synthetic peptides, known as growth factor analogs, are easier to produce than natural growth factors or growth factors derived from recombinant techniques.

Tom Rouech, BioSET's president, said, "This newly patented technology builds upon our core method for making synthetic biomimedic peptides that we developed with Brookhaven Lab scientists almost a decade ago. We can now make peptides in higher yields, with more purity, and more cost-effectively than we had done previously."

Louis Pea, the principal researcher at Brookhaven Lab who developed the technology with BioSET, added, "This new platform technology will allow us to make multiple variations of peptides, which can lead to numerous applications in tissue repair. For example, bandages can be designed with growth factor analogs to apply to wounds, or coatings for surgical implants can be made for better localized healing. I'm glad that this technology has progressed so well and may benefit many people with soft-tissue injuries." A soft tissue injury results from damage to muscles, ligaments, or tendons.

BioSET has sublicensed the newly patented technology to Tornier, Inc., a global orthopedic company, to develop synthetic peptides for sports medicine applications, with emphasis on rotator cuff, shoulder, knee, and elbow injuries. The company will develop novel soft-tissue grafts with synthetic human growth factor for orthopedic markets.

"Assessing the role of tissue regeneration and clinical testing of the new growth factor analogs is the next step as we bring these important new treatments to surgeons and their patients," Rouech said. "A previously patented growth factor analog, B2A, designed to improve bone repair, is currently in clinical trials for spinal fusion of the lower back and we remain very encouraged by the early results of these studies."

The U.S. Department of Energy's Office of Science, the National Institutes of Health, and BioSET funded the initial research to develop this growth factor technology. One of three patents related to this technology issued to BSA and BioSET, the new patent (US 7,700,563 B2), was issued on April 20, 2010.


'/>"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. USF receives patent for technology to improve treatment for neurodegenerative diseases
2. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
3. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
4. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
5. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
6. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
7. GenomeQuest Upgrades Online Patent Searching
8. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
9. Drug Patents in India Helping Promote Innovation
10. Innovative Patent-pending Shapewear Technology Introduced for Jeans.
11. Wind Power Systems, LLC (WPS) Launches PPM to Raise $2.5M for Earth Friendly Patent Pending "Small Wind" Turbine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... of the much-anticipated fall event , Look Awesome This Autumn with CoolSculpting®. ... consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is Houston’s ...
(Date:9/20/2017)... ... 20, 2017 , ... Each year Athletic Trainers from around ... Association Annual Clinical Symposium and Expo. New research is revealed, evidence based practice ... are acknowledged by their peers with accolades and highly prestigious awards. This past ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Americans at risk of price gouging for their prescription drugs, according to a ... “Because Medicare isn’t negotiating on our behalf, there’s no consistency in drug pricing ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second ... of God; Second Edition” is the creation of published author, Brooks Rathell. , “We ... to talk to you about the financial favor of God. Not only does it ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
Breaking Medicine Technology: